AIM Stock Overview
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
AIM ImmunoTech Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.40|
|52 Week High||US$1.43|
|52 Week Low||US$0.39|
|1 Month Change||-31.92%|
|3 Month Change||-39.73%|
|1 Year Change||-69.68%|
|3 Year Change||1.32%|
|5 Year Change||-97.49%|
|Change since IPO||-99.97%|
Recent News & Updates
|AIM||US Biotechs||US Market|
Return vs Industry: AIM underperformed the US Biotechs industry which returned -10.3% over the past year.
Return vs Market: AIM underperformed the US Market which returned -16.1% over the past year.
|AIM Average Weekly Movement||7.6%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: AIM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AIM's weekly volatility (8%) has been stable over the past year.
About the Company
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
AIM ImmunoTech Inc. Fundamentals Summary
|AIM fundamental statistics|
Is AIM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AIM income statement (TTM)|
|Cost of Revenue||US$176.00k|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.43|
|Net Profit Margin||-15,482.96%|
How did AIM perform over the long term?See historical performance and comparison